Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean I Tracy

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Haematologica|November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppressionSean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood|February 5, 2026
Blinatumomab Nonresponse Correlates with Poor Survival After BrexucabtageneHrishikesh Krishna Srinagesh, Vishal K Gupta, Amy Zhang, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Haematologica|November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppressionSean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood|February 5, 2026
Blinatumomab Nonresponse Correlates with Poor Survival After BrexucabtageneHrishikesh Krishna Srinagesh, Vishal K Gupta, Amy Zhang, et al.
Pageof 2